TTT

TRACON Pharmaceuticals, Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪3.83 M‬USD
‪−3.59 M‬USD
‪12.05 M‬USD
‪2.47 M‬
Beta (1Y)
1.48

About TRACON Pharmaceuticals, Inc.

CEO
Charles P. Theuer
Headquarters
San Diego
Employees (FY)
17
Founded
2004
FIGI
BBG000R33BY8
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types, TRC205 created for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of TCON is 1.43 USD — it has decreased by 6.54% in the past 24 hours. Watch TRACON Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange TRACON Pharmaceuticals, Inc. stocks are traded under the ticker TCON.
TCON stock has fallen by 21.43% compared to the previous week, the month change is a 16.37% fall, over the last year TRACON Pharmaceuticals, Inc. has showed a 88.65% decrease.
We've gathered analysts' opinions on TRACON Pharmaceuticals, Inc. future price: according to them, TCON price has a max estimate of 55.00 USD and a min estimate of 6.00 USD. Watch TCON chart and read a more detailed TRACON Pharmaceuticals, Inc. stock forecast: see what analysts think of TRACON Pharmaceuticals, Inc. and suggest that you do with its stocks.
TCON reached its all-time high on Mar 3, 2015 with the price of 4200.00 USD, and its all-time low was 1.59 USD and was reached on Apr 16, 2024. View more price dynamics on TCON chart.
See other stocks reaching their highest and lowest prices.
TCON stock is 11.26% volatile and has beta coefficient of 1.48. Track TRACON Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is TRACON Pharmaceuticals, Inc. there?
Today TRACON Pharmaceuticals, Inc. has the market capitalization of ‪3.83 M‬, it has decreased by 0.78% over the last week.
Yes, you can track TRACON Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
TRACON Pharmaceuticals, Inc. is going to release the next earnings report on Aug 7, 2024. Keep track of upcoming events with our Earnings Calendar.
TCON earnings for the last quarter are −1.33 USD per share, whereas the estimation was −1.19 USD resulting in a −11.76% surprise. The estimated earnings for the next quarter are −1.41 USD per share. See more details about TRACON Pharmaceuticals, Inc. earnings.
TRACON Pharmaceuticals, Inc. revenue for the last quarter amounts to ‪100.00 K‬ USD despite the estimated figure of 0 USD. In the next quarter revenue is expected to reach 0 USD.
TCON net income for the last quarter is ‪−3.17 M‬ USD, while the quarter before that showed ‪439.00 K‬ USD of net income which accounts for −821.64% change. Track more TRACON Pharmaceuticals, Inc. financial stats to get the full picture.
No, TCON doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 19, 2024, the company has 17.00 employees. See our rating of the largest employees — is TRACON Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. TRACON Pharmaceuticals, Inc. EBITDA is ‪−2.78 M‬ USD, and current EBITDA margin is −57.15%. See more stats in TRACON Pharmaceuticals, Inc. financial statements.
Like other stocks, TCON shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TRACON Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So TRACON Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating TRACON Pharmaceuticals, Inc. stock shows the strong sell signal. See more of TRACON Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.